Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)

Oren Pleniceanu; Racheli Shukrun; Dorit Omer; Einav Vax; Itamar Kanter; Klaudyna Dziedzic; Naomi Pode-Shakked; Michal Mark-Daniei; Sara Pri-Chen; Yehudit Gnatek; Hadas Alfandary; Nira Varda-Bloom; Dekel D. Bar-Lev; Naomi Bollag; Rachel Shtainfeld; Leah Armon; Achia Urbach; Tomer Kalisky; Arnon Nagler; Orit Harari-Steinberg; Jack L. Arbiser; Benjamin Dekel

doi:10.15252/emmm.201708507

Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)

Oren Pleniceanu, Racheli Shukrun, Dorit Omer, Einav Vax, Itamar Kanter, Klaudyna Dziedzic, Naomi Pode-Shakked, Michal Mark-Daniei, Sara Pri-Chen, Yehudit Gnatek, Hadas Alfandary, Nira Varda-Bloom, Dekel D. Bar-Lev, Naomi Bollag, Rachel Shtainfeld, Leah Armon, Achia Urbach, Tomer Kalisky, Arnon Nagler, Orit Harari-SteinbergJack L. Arbiser, Benjamin Dekel

Clinical Departments

Research output: Contribution to journal › Comment/debate

Abstract

The authors of the above research article have informed the journal that although the paper uses the official nomenclature PPARG to signify the peroxisome proliferator-activated receptor gamma gene, the most prevalent term used in the literature is PPARγ. Therefore, the title, abstract, and keywords have been changed and now apply the latter term to improve searchability. The authors apologize for any inconvenience caused.

Original language	English
Pages (from-to)	1763
Number of pages	1
Journal	EMBO Molecular Medicine
Volume	9
Issue number	12
DOIs	https://doi.org/10.15252/emmm.201708507
State	Published - Dec 2017

Access to Document

10.15252/emmm.201708507

Fingerprint

Dive into the research topics of 'Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)'. Together they form a unique fingerprint.

Cite this

Pleniceanu, O., Shukrun, R., Omer, D., Vax, E., Kanter, I., Dziedzic, K., Pode-Shakked, N., Mark-Daniei, M., Pri-Chen, S., Gnatek, Y., Alfandary, H., Varda-Bloom, N., Bar-Lev, D. D., Bollag, N., Shtainfeld, R., Armon, L., Urbach, A., Kalisky, T., Nagler, A., ... Dekel, B. (2017). Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111). EMBO Molecular Medicine, 9(12), 1763. https://doi.org/10.15252/emmm.201708507

Pleniceanu, Oren ; Shukrun, Racheli ; Omer, Dorit et al. / Corrigendum to : Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111). In: EMBO Molecular Medicine. 2017 ; Vol. 9, No. 12. pp. 1763.

@article{5abbc151d55c4decbbc522f67e7884f0,

title = "Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)",

abstract = "The authors of the above research article have informed the journal that although the paper uses the official nomenclature PPARG to signify the peroxisome proliferator-activated receptor gamma gene, the most prevalent term used in the literature is PPARγ. Therefore, the title, abstract, and keywords have been changed and now apply the latter term to improve searchability. The authors apologize for any inconvenience caused.",

author = "Oren Pleniceanu and Racheli Shukrun and Dorit Omer and Einav Vax and Itamar Kanter and Klaudyna Dziedzic and Naomi Pode-Shakked and Michal Mark-Daniei and Sara Pri-Chen and Yehudit Gnatek and Hadas Alfandary and Nira Varda-Bloom and Bar-Lev, {Dekel D.} and Naomi Bollag and Rachel Shtainfeld and Leah Armon and Achia Urbach and Tomer Kalisky and Arnon Nagler and Orit Harari-Steinberg and Arbiser, {Jack L.} and Benjamin Dekel",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Published under the terms of the CC BY 4.0 license",

year = "2017",

month = dec,

doi = "10.15252/emmm.201708507",

language = "אנגלית",

volume = "9",

pages = "1763",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

publisher = "Wiley-Blackwell",

number = "12",

}

Pleniceanu, O, Shukrun, R, Omer, D, Vax, E, Kanter, I, Dziedzic, K, Pode-Shakked, N, Mark-Daniei, M, Pri-Chen, S, Gnatek, Y, Alfandary, H, Varda-Bloom, N, Bar-Lev, DD, Bollag, N, Shtainfeld, R, Armon, L, Urbach, A, Kalisky, T, Nagler, A, Harari-Steinberg, O, Arbiser, JL & Dekel, B 2017, 'Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)', EMBO Molecular Medicine, vol. 9, no. 12, pp. 1763. https://doi.org/10.15252/emmm.201708507

Corrigendum to : Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111). / Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit et al.

In: EMBO Molecular Medicine, Vol. 9, No. 12, 12.2017, p. 1763.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to

T2 - Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)

AU - Pleniceanu, Oren

AU - Shukrun, Racheli

AU - Omer, Dorit

AU - Vax, Einav

AU - Kanter, Itamar

AU - Dziedzic, Klaudyna

AU - Pode-Shakked, Naomi

AU - Mark-Daniei, Michal

AU - Pri-Chen, Sara

AU - Gnatek, Yehudit

AU - Alfandary, Hadas

AU - Varda-Bloom, Nira

AU - Bar-Lev, Dekel D.

AU - Bollag, Naomi

AU - Shtainfeld, Rachel

AU - Armon, Leah

AU - Urbach, Achia

AU - Kalisky, Tomer

AU - Nagler, Arnon

AU - Harari-Steinberg, Orit

AU - Arbiser, Jack L.

AU - Dekel, Benjamin

PY - 2017/12

Y1 - 2017/12

N2 - The authors of the above research article have informed the journal that although the paper uses the official nomenclature PPARG to signify the peroxisome proliferator-activated receptor gamma gene, the most prevalent term used in the literature is PPARγ. Therefore, the title, abstract, and keywords have been changed and now apply the latter term to improve searchability. The authors apologize for any inconvenience caused.

AB - The authors of the above research article have informed the journal that although the paper uses the official nomenclature PPARG to signify the peroxisome proliferator-activated receptor gamma gene, the most prevalent term used in the literature is PPARγ. Therefore, the title, abstract, and keywords have been changed and now apply the latter term to improve searchability. The authors apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85035800735&partnerID=8YFLogxK

U2 - 10.15252/emmm.201708507

DO - 10.15252/emmm.201708507

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 29196313

AN - SCOPUS:85035800735

SN - 1757-4676

VL - 9

SP - 1763

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 12

ER -

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K et al. Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111). EMBO Molecular Medicine. 2017 Dec;9(12):1763. doi: 10.15252/emmm.201708507

Corrigendum to: Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target (EMBO Mol Med, (2017), 9, (508-530), 10.15252/emmm.201506111)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this